The Beatles sang about the “long and winding road,” but nuclear medicine and molecular imaging’s Road to RSNA 2026 is more like traveling on the Autobahn. RSNA has retired its standalone scientific session on new radiotracers, which has been a fixture in recent years, and added a dedicated theranostics sessions in its place. 
Here, we’ve focused on studies in the scientific sessions, where in addition to theranostics, attendees can expect to find research on breast cancer, lymphoma and multiple myeloma, abdominal, gastrointestinal, and genitourinary disease, cardiology, and molecular imaging of CNS pathology. Radiotracers provide key highlights in most sessions.
Kicking off the show on Sunday, two head-to-head PET studies are offered in the breast cancer session. F-18 FDG-PET goes against breast MRI in preoperative staging of invasive ductal carcinoma, while Ga-68 RGD PET is compared to FDG-PET across breast cancer subtypes. Check it out to see which techniques come out on top.
Do pregnant nuclear medicine trainees need to worry about radiation exposure? A study in a general nuclear medicine session on Monday answers that question. Also on Monday, a first-in-human study tests an oral PET radiotracer for imaging thoracic duct lymphatic flow with anatomic precision.
Of the theranostics sessions, one offers research on endocrine and neuroendocrine disease and the other on prostate cancer. In the endocrine session, we've highlighted a study that asks whether post-therapy planar imaging can predict treatment outcomes after Lutathera. In the prostate cancer session, a group investigated whether two leading PSMA tracers, F-18 PSMA-DCFPyL and Ga-68 PSMA-11, can be used interchangeably when selecting patients for Pluvicto therapy.
AI features in multiple sessions this year. Can a model that combines PSMA-PET features and lab values predict which prostate cancer patients will respond to Pluvicto? A Wednesday session addresses that question. And on Thursday, deep learning takes on a protocol challenge: synthesizing standard brain FDG-PET reconstructions from data acquired as early as 10 minutes post-injection.
Education exhibits, Learning Center Theater presentations, educational courses, and 14 scientific poster sessions with dozens of studies each round out the week. Below is just a sample of the content on offer. For more information on those presentations and other abstracts, see the full RSNA 2026 meeting program.
FDG-PET tops breast MRI in invasive ductal carcinoma staging
Sunday, November 29 | 10:30 a.m.-11:30 a.m. | S2-SSNMMI01-1 | Room S405
F-18 FDG-PET scans match breast MRI for sensitivity while outperforming it on specificity in preoperative staging of invasive ductal carcinoma (IDC), according to research in this session.
Ga-68 RGD PET triples FDG tumor-to-background ratio in breast cancer pilot
Sunday, November 29 | 10:30 a.m.-11:30 a.m. | S2-SSNMMI01-6 | Room S405
Gallium-68 (Ga-68) arginine-glycine-aspartate (RGD) PET/CT offers complementary staging value to F-18 FDG-PET/CT in breast cancer, suggest findings from a small pilot study in this session.
Do pregnant nuclear medicine trainees need to worry about radiation?
Monday, November 30 | 8:00 a.m.-9:00 a.m. | M1-SSNMMI02-1 | Room S405
Pregnant nuclear medicine resident physicians accumulate radiation doses well below occupational safety limits during training, even under worst-case assumptions, research in this session suggests.
Oral PET tracer enables visualization of thoracic duct lymphatic flow
Monday, November 30 | 8:00 a.m.-9:00 a.m. | M1-SSNMMI02-8 | Room S405
An orally administered encapsulated fatty acid radiotracer successfully images thoracic duct lymphatic flow with anatomic precision on PET/CT, suggest preliminary findings from a first-in-human study presented in this session.
AI predicts survival in metastatic prostate cancer
Tuesday, December 1 | 3:00 p.m.-4:00 p.m. | T7-SSRO02-7 | Room S401CD
For patients with metastatic prostate cancer, deep learning applied to PSMA-PET scans may be better for predicting survival than existing risk tools, according to this presentation.
FAPI-PET uptake rises with liver fibrosis stage
Tuesday, December 1 | 4:30 p.m.-5:30 p.m. | T8-SSNMMI04-4 | Room S405
Whole-liver uptake on gallium-68 (Ga-68) fibroblast activation protein inhibitor (FAPI) PET increased significantly as fibrosis stage worsened in patients with chronic liver disease, according to a prospective study presented in this session.
FDG-PET/CT tracks response, guides biopsy in resistant GIST
Tuesday, December 1 | 4:30 p.m.-5:30 p.m. | T8-SSNMMI04-6 | Room S405
F-18 FDG-PET/CT can monitor treatment response and direct biopsy toward metabolically active lesions in patients with gastrointestinal stromal tumors (GIST) that have stopped responding to standard therapy, researchers will report in this session.
Post-therapy planar imaging predicts Lutathera response in NETs
Wednesday, December 2 | 8:00 a.m.-9:00 a.m. | W1-SSNMMI05-3 | Room S405
Whole-body retention measured on post-therapy planar imaging predicts treatment response in patients with neuroendocrine tumors (NETs) receiving lutetium-177 (Lu-177) DOTATATE (Lutathera), according to a presentation in this session.
Can an AI model predict Pluvicto treatment response?
Wednesday, December 2 | 1:30 p.m.-2:30 p.m. | W6-SSNMMI06-2 | Room S405
An algorithm that combines PSMA-PET imaging features with routine lab values may help predict which patients with metastatic castration-resistant prostate cancer (mCRPC) will respond to Pluvicto radioligand therapy, according to this presentation.
PSMA tracers agree on Pluvicto eligibility, diverge on tumor volume
Wednesday, December 2 | 1:30 p.m.-2:30 p.m. | W6-SSNMMI06-5 | Room S405
Two U.S.-cleared PSMA PET radiotracers are clinically interchangeable for determining eligibility for Pluvicto treatment in patients with mCRPC,, according to research in this session.
PSMA-PET upstages men with high-risk or recurrent prostate cancer
Wednesday, December 2 | 1:30 p.m.-2:30 p.m. | W6-SSNMMI06-8 | Room S405
F-18 prostate-specific membrane antigen (PSMA) PET upstaged nearly four in 10 men with either newly diagnosed high-risk or biochemically recurrent prostate cancer, according to secondary-endpoint data from a phase III trial being reported in this session.
New PET tracer differentiates cardiac amyloidosis subtypes
Thursday, December 3 | 8:00 a.m.-9:00 a.m. | R1-SSNMMI07-4 | Room S405
PET/CT with a novel radiotracer initially developed for amyloid imaging in Alzheimer’s disease may detect and help subtype cardiac amyloidosis, suggest preliminary findings from a small clinical evaluation presented in this session.
Early F-18 MK-6240 tau PET scans feasible
Thursday, December 3 | 1:30 p.m.-2:30 p.m. | R6-SSNMMI08-4 | Room S405
F-18 MK-6240 tau PET scans acquired at 40 to 60 minutes post-injection discriminate Alzheimer disease tau burden as accurately as standard 90- to 120-minute scans, according to research in this session.
